null<\/span>melemapharma.com<\/a>)<\/p>\nis the Chief Scientific Officer of MELEMA Pharma GmbH. He is pharmacist and pharmacologist and has more than 20 years of management experience in the R&D area of the pharmaceutical and biotechnological industry. He was the former Head of the R&D Division of MADAUS AG, Cologne, and is one of the founders of MELEMA. In January 1999, he was awarded the \u201dCologne Innovation Prize 1998\u201d for the idea, the concept as well as the research and development work on the Aviscumine project.<\/p>\n
Cooperations<\/h3>\n
With Professor Dr. Ulrike Naumann, Hertie Institute for Clinical Brain Research, Dept. Vascular Neurology, Laboratory for Molecular Neuro-Oncology at the University of T\u00fcbingen and Professor Dr. Michel Mittelbronn, National Center of Pathology (NCP) & Luxembourg Center of Neuropathology (LCNP) of the Laboratoire national de sant\u00e9 (LNS), Dudelange \/ Luxembourg, in-vitro and in-vivo studies (mouse model) on the effect of ME 503 on destructing invasive growth of glioblastoma are ongoing.<\/p>\n
Professor Peiying Yang, Ph.D., Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas, MD Anderson Cancer Center, Houston \/ Texas, is carrying out in vivo studies on the effectiveness of ME-503 and its mechanism of action.<\/p>\n
<\/p>\n
\n <\/p>\n
As part of a service agreement between MELEMA and Lonza, studies on the influence of ME-503 on DC and T cell stimulation were completed. The analysis of such T cell responses is a frequently used tool to control the activation of the immune system<\/p>\n
About Lonza<\/strong><\/p>\nLonza is one of the world’s leading and most renowned suppliers for the pharmaceutical, biotech, and specialty chemical markets. More information is available at www.lonza.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"Overview MELEMA Pharma is a private biopharmaceutical company that develops derivatives of natural substances for the immunotherapeutic treatment of cancer and for the activation of the immune system. The company was founded in 2013 and develops its substances in collaboration with partners from academia, hospitals, and industry. Before the products are brought into partnerships, the company brings its substances through preclinical and clinical development to proof of effectiveness in humans. The conclusion of possible partnerships is conceivable at every stage of development. The most advanced product of MELEMA is ME-503, a new active ingredient with cytolytic\/cytostatic and immunotherapeutic activity that triggers programmed cell death (apoptosis) of tumor cells and activates immune functions against cancer cells. History MELEMA Pharma GmbH […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2","page","type-page","status-publish","hentry"],"yoast_head":"\n
About Melema - MELEMA Pharma GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"About Melema - MELEMA Pharma GmbH\" \/>\n<meta property=\"og:description\" content=\"Overview MELEMA Pharma is a private biopharmaceutical company that develops derivatives of natural substances for the immunotherapeutic treatment of cancer and for the activation of the immune system. The company was founded in 2013 and develops its substances in collaboration with partners from academia, hospitals, and industry. Before the products are brought into partnerships, the company brings its substances through preclinical and clinical development to proof of effectiveness in humans. The conclusion of possible partnerships is conceivable at every stage of development. The most advanced product of MELEMA is ME-503, a new active ingredient with cytolytic\/cytostatic and immunotherapeutic activity that triggers programmed cell death (apoptosis) of tumor cells and activates immune functions against cancer cells. History MELEMA Pharma GmbH […]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/\" \/>\n<meta property=\"og:site_name\" content=\"MELEMA Pharma GmbH\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-22T13:14:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/07\/2237-300-300x235.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/melemapharma.de\\\/ueber-melema-immuntherapie-von-krebserkrankungen\\\/\",\"url\":\"http:\\\/\\\/melemapharma.de\\\/ueber-melema-immuntherapie-von-krebserkrankungen\\\/\",\"name\":\"About Melema - MELEMA Pharma GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/melemapharma.de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/ueber-melema-immuntherapie-von-krebserkrankungen\\\/#primaryimage\"},\"image\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/ueber-melema-immuntherapie-von-krebserkrankungen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/melemapharma.de\\\/wp-content\\\/uploads\\\/2014\\\/07\\\/2237-300-300x235.jpg\",\"datePublished\":\"2014-07-17T12:11:53+00:00\",\"dateModified\":\"2020-04-22T13:14:52+00:00\",\"breadcrumb\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/ueber-melema-immuntherapie-von-krebserkrankungen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\\\/\\\/melemapharma.de\\\/ueber-melema-immuntherapie-von-krebserkrankungen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\\\/\\\/melemapharma.de\\\/ueber-melema-immuntherapie-von-krebserkrankungen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/melemapharma.de\\\/wp-content\\\/uploads\\\/2014\\\/07\\\/2237-300-300x235.jpg\",\"contentUrl\":\"https:\\\/\\\/melemapharma.de\\\/wp-content\\\/uploads\\\/2014\\\/07\\\/2237-300-300x235.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/melemapharma.de\\\/ueber-melema-immuntherapie-von-krebserkrankungen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/melemapharma.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00dcber Melema\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/melemapharma.de\\\/#website\",\"url\":\"https:\\\/\\\/melemapharma.de\\\/\",\"name\":\"MELEMA Pharma GmbH\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/melemapharma.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"About Melema - MELEMA Pharma GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/","og_locale":"en_US","og_type":"article","og_title":"About Melema - MELEMA Pharma GmbH","og_description":"Overview MELEMA Pharma is a private biopharmaceutical company that develops derivatives of natural substances for the immunotherapeutic treatment of cancer and for the activation of the immune system. The company was founded in 2013 and develops its substances in collaboration with partners from academia, hospitals, and industry. Before the products are brought into partnerships, the company brings its substances through preclinical and clinical development to proof of effectiveness in humans. The conclusion of possible partnerships is conceivable at every stage of development. The most advanced product of MELEMA is ME-503, a new active ingredient with cytolytic\/cytostatic and immunotherapeutic activity that triggers programmed cell death (apoptosis) of tumor cells and activates immune functions against cancer cells. History MELEMA Pharma GmbH […]","og_url":"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/","og_site_name":"MELEMA Pharma GmbH","article_modified_time":"2020-04-22T13:14:52+00:00","og_image":[{"url":"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/07\/2237-300-300x235.jpg","type":"","width":"","height":""}],"twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/","url":"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/","name":"About Melema - MELEMA Pharma GmbH","isPartOf":{"@id":"https:\/\/melemapharma.de\/#website"},"primaryImageOfPage":{"@id":"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/#primaryimage"},"image":{"@id":"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/#primaryimage"},"thumbnailUrl":"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/07\/2237-300-300x235.jpg","datePublished":"2014-07-17T12:11:53+00:00","dateModified":"2020-04-22T13:14:52+00:00","breadcrumb":{"@id":"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/#primaryimage","url":"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/07\/2237-300-300x235.jpg","contentUrl":"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/07\/2237-300-300x235.jpg"},{"@type":"BreadcrumbList","@id":"http:\/\/melemapharma.de\/ueber-melema-immuntherapie-von-krebserkrankungen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/melemapharma.de\/"},{"@type":"ListItem","position":2,"name":"\u00dcber Melema"}]},{"@type":"WebSite","@id":"https:\/\/melemapharma.de\/#website","url":"https:\/\/melemapharma.de\/","name":"MELEMA Pharma GmbH","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/melemapharma.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/pages\/2","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/comments?post=2"}],"version-history":[{"count":24,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/pages\/2\/revisions"}],"predecessor-version":[{"id":382,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/pages\/2\/revisions\/382"}],"wp:attachment":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/media?parent=2"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"4.0.4\"](\"https:\/\/melemapharma.de\/wp-content\/uploads\/2014\/07\/2237-300.jpg\")
<\/a>MELEMA Pharma is a private biopharmaceutical company that develops derivatives of natural substances for the immunotherapeutic treatment of cancer and for the activation of the immune system.<\/p>\n